Eris Lifesciences has reached an agreement to purchase Strides Shasun’s Indian generics business for $76.73m.

Under the agreement, Eris will take over the marketing and distribution rights for more than 130 products across multiple therapeutic areas owned by the generics business.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition is expected to close on 30 November and will boost Eris’ central nervous system (CNS) and gastro-intestinal therapies.

Sichuan Languang Development is set to issue asset-backed notes to raise $209.6m, having received the same statutory approvals.

Based in China, Sichuan Languang is engaged in manufacturing and distribution of pharmaceuticals.

Guoxin Securities and China Minsheng Banking will serve as underwriters for the issue.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Sichuan Languang Development is set to issue asset-backed notes to raise $209.6m, having received the same statutory approvals.”

Xiangxue Pharmaceutical, a Chinese pharmaceutical firm, plans to raise $75.28m from qualified institutional investors by issuing corporate bonds due 2022.

The funds will be utilised to clear the company’s existing liability on corporate bonds services.

Navamedic and G. Pohl-Boskamp GmbH & Co KG have joined forces to roll out the latter’s nitroglycerin sublingual powder formulation GoNitro in Norway.

Headquartered in Norway, Navamedic is engaged in the marketing and distribution of pharmaceutical products.

GoNitro provides acuter relief of an attack or prophylaxis of angina pectoris.